• Something wrong with this record ?

Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox"

Z. Moťovská, P. Widimský, R. Petr, D. Bílková, I. Marinov, S. Šimek, P. Kala, Study Investigators PRAGUE-8

. 2009 ; 53 (5) : 368-372.

Language English Country United States

Document type Randomized Controlled Trial, Research Support, Non-U.S. Gov't

E-resources

NLK Journals@Ovid Ovid Full Text from 2000-01-01 to 2010-02-01

PURPOSE: The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. METHODS: In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention. Flow cytometric analysis of the vasodilator-stimulated phosphoprotein phosphorylation state was used. Independent predictors that influenced clopidogrel action were identified using linear regression. RESULTS: There was no correlation between baseline platelet reactivity index (PRI) and severity of coronary atherosclerosis; mean index of platelet reactivity for a nonsignificant lesion was 72% +/- 5.98% and for a significant lesion 70.08% +/- 8.43%. The highest proportion of low responders was patients with diabetes (50% at 28 hours). Among tobacco smokers, the response to clopidogrel occurred quickly and 80% of smokers had effective inhibition of PRI, 12 hours after drug use. After adjustments, tobacco smoking was an independent predictor for the most robust drop of PRI 12 hours after clopidogrel (P = 0.027). The magnitude of total decrease of PRI at 28 hours was not significantly influenced by cigarette smoking (P = 0.12). Linear regression showed that patients on statin therapy had a better response to clopidogrel than those without statins-the mean decrease of PRI at 28 hours was significantly higher (P = 0.02) among these patients (40.0 vs. 27.6). CONCLUSIONS: In stable coronary artery disease, no correlation exists between baseline PRI and the severity and extent of coronary atherosclerosis. A high loading dose of clopidogrel does not satisfactorily suppress enhanced PRI in patients with diabetes. Cigarette smoking is independently associated with a prompt antiplatelet response to clopidogrel. Ongoing statin therapy is an independent determinant of more effective clopidogrel-mediated inhibition of platelet reactivity.

000      
05377naa 2200721 a 4500
001      
bmc11019678
003      
CZ-PrNML
005      
20121112123319.0
008      
110714s2009 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Moťovská, Zuzana $7 xx0104795
245    10
$a Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox" / $c Z. Moťovská, P. Widimský, R. Petr, D. Bílková, I. Marinov, S. Šimek, P. Kala, Study Investigators PRAGUE-8
314    __
$a Third Medical Faculty, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. zuzana.motovska@iex.cz
520    9_
$a PURPOSE: The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. METHODS: In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention. Flow cytometric analysis of the vasodilator-stimulated phosphoprotein phosphorylation state was used. Independent predictors that influenced clopidogrel action were identified using linear regression. RESULTS: There was no correlation between baseline platelet reactivity index (PRI) and severity of coronary atherosclerosis; mean index of platelet reactivity for a nonsignificant lesion was 72% +/- 5.98% and for a significant lesion 70.08% +/- 8.43%. The highest proportion of low responders was patients with diabetes (50% at 28 hours). Among tobacco smokers, the response to clopidogrel occurred quickly and 80% of smokers had effective inhibition of PRI, 12 hours after drug use. After adjustments, tobacco smoking was an independent predictor for the most robust drop of PRI 12 hours after clopidogrel (P = 0.027). The magnitude of total decrease of PRI at 28 hours was not significantly influenced by cigarette smoking (P = 0.12). Linear regression showed that patients on statin therapy had a better response to clopidogrel than those without statins-the mean decrease of PRI at 28 hours was significantly higher (P = 0.02) among these patients (40.0 vs. 27.6). CONCLUSIONS: In stable coronary artery disease, no correlation exists between baseline PRI and the severity and extent of coronary atherosclerosis. A high loading dose of clopidogrel does not satisfactorily suppress enhanced PRI in patients with diabetes. Cigarette smoking is independently associated with a prompt antiplatelet response to clopidogrel. Ongoing statin therapy is an independent determinant of more effective clopidogrel-mediated inhibition of platelet reactivity.
590    __
$a bohemika - dle Pubmed
650    _2
$a věkové faktory $7 D000367
650    _2
$a senioři $7 D000368
650    _2
$a balónková koronární angioplastika $7 D015906
650    _2
$a Aspirin $x terapeutické užití $7 D001241
650    _2
$a index tělesné hmotnosti $7 D015992
650    _2
$a molekuly buněčné adheze $x metabolismus $7 D015815
650    _2
$a koronární angiografie $7 D017023
650    _2
$a nemoci koronárních tepen $x farmakoterapie $x komplikace $x radiografie $x terapie $7 D003324
650    _2
$a diabetes mellitus 2. typu $x komplikace $x patofyziologie $7 D003924
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a heparin $x terapeutické užití $7 D006493
650    _2
$a lidé $7 D006801
650    _2
$a statiny $x terapeutické užití $7 D019161
650    _2
$a hypercholesterolemie $x epidemiologie $x patofyziologie $7 D006937
650    _2
$a hypertenze $x komplikace $x patofyziologie $7 D006973
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a mikrofilamentové proteiny $x metabolismus $7 D008840
650    _2
$a fosfoproteiny $x metabolismus $7 D010750
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x terapeutické užití $7 D010975
650    _2
$a renální insuficience $x komplikace $x patofyziologie $7 D051437
650    _2
$a sexuální faktory $7 D012737
650    _2
$a kouření $x škodlivé účinky $7 D012907
650    _2
$a tiklopidin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D013988
650    _2
$a výsledek terapie $7 D016896
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Widimský, Petr, $d 1954- $7 jn20000402682
700    1_
$a Petr, Róbert $7 xx0111623
700    1#
$a Mocová, Danuše. $7 xx0193836
700    1_
$a Marinov, Iuri
700    1_
$a Šimek, Stanislav, $d 1963- $7 ola2006345268
700    1_
$a Kala, Petr, $d 1965- $7 xx0043092
700    1_
$a PRAGUE-8, Study Investigators
773    0_
$t Journal of Cardiovascular Pharmacology $w MED00002571 $g Roč. 53, č. 5 (2009), s. 368-372
910    __
$a ABA008 $b x $y 2
990    __
$a 20110715115142 $b ABA008
991    __
$a 20121112123333 $b ABA008
999    __
$a ok $b bmc $g 864506 $s 729557
BAS    __
$a 3
BMC    __
$a 2009 $x MED00002571 $b 53 $c 5 $d 368-372 $m Journal of cardiovascular pharmacology $n J Cardiovasc Pharmacol
LZP    __
$a 2011-3B09/Bjvme

Find record